Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasugrel vs clopidogrel pharmacokinetic and pharmacodynamic comparison by body weight in aspirin-treated stable coronary artery disease
NL-OMON34026Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Trial of prasugrel, clopidogrel and aspirin in coronary arteriosclerosis (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Primary pharmacodynamic endpoint, Safety endpoints and 2 more. Started Oct 2010; status: active, not recruiting.
02
Drugs
prasugrelclopidogrelaspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON34026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34026.